Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Inflammatory bowel diseases: conservative therapy].

G Bansky

    Therapeutische Umschau. Revue Therapeutique
    |July 1, 1991
    PubMed
    Summary

    Newer treatments for inflammatory bowel diseases (IBD) show promise. Mesalazine offers an effective alternative to sulfasalazine for ulcerative colitis with fewer side effects, while other drugs manage Crohn's disease.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effect of ursodeoxycholic acid in acute viral hepatitis.

    Journal of clinical gastroenterology·1999
    Same author

    [Neuroendocrine tumors of the stomach (stomach carcinoid)].

    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis·1994
    Same author

    [Current possibilities in the therapy of hepatic encephalopathy].

    Schweizerische medizinische Wochenschrift·1990
    Same author

    [Report of experiences with 31 surgically treated patients with deformity of the femur shaft].

    Unfallchirurgie·1989
    Same author

    Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans.

    Gastroenterology·1989
    Same author

    [Surgical ulcer prevention in transplantation surgery].

    Helvetica chirurgica acta·1988

    Area of Science:

    • Gastroenterology
    • Internal Medicine
    • Pharmacology

    Context:

    • Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, represent significant challenges in medical treatment.
    • Advances in understanding IBD pathogenesis have led to the development of novel therapeutic strategies.
    • Controlled clinical trials are crucial for evaluating the efficacy and safety of new IBD treatments.

    Purpose:

    • To review recent advancements in the medical management of inflammatory bowel diseases.
    • To highlight the efficacy and safety profiles of newly developed and established therapeutic agents.
    • To discuss the current role and future prospects of various treatment modalities for IBD.

    Summary:

    • Mesalazine, containing 5-aminosalicylic acid, demonstrates comparable efficacy to sulfasalazine in ulcerative colitis treatment but with a reduced incidence of adverse effects.
    • Corticosteroids remain the cornerstone for managing severe inflammatory bowel disease exacerbations across all forms.
    • Immunosuppressive agents like 6-mercaptopurine and azathioprine serve as valuable second-line options for refractory Crohn's disease, while metronidazole is the primary antibiotic for its treatment.

    Impact:

    • Provides clinicians with an updated overview of evidence-based treatment options for inflammatory bowel diseases.
    • Informs therapeutic decision-making by comparing the efficacy and side effect profiles of different medications.
    • Suggests areas for future research, particularly regarding the role of cyclosporine and dietary interventions in IBD management.

    Related Experiment Videos